Synthetic surfactants: The search goes on

Pediatrics

Volumn 115, Issue 4, 2005, Pages 1075-1076

  Kattwinkel, John ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; ARTIFICIAL LUNG SURFACTANT; BERACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; PHOSPHOLIPID; POLYPEPTIDE; PORACTANT; PUMACTANT; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; BIOLOGICAL PRODUCT; DRUG DERIVATIVE; FATTY ALCOHOL; PHOSPHATIDYLGLYCEROL; PROTEIN;

EXPERIMENTAL MODEL; HUMAN; HYALINE MEMBRANE DISEASE; LUNG ALVEOLUS SURFACE TENSION; LUNG DEVELOPMENT; LUNG DISEASE; LUNG FUNCTION; NONHUMAN; NOTE; PRIORITY JOURNAL; DRUG COMBINATION; LUNG DYSPLASIA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; BIOLOGICAL PRODUCTS; BRONCHOPULMONARY DYSPLASIA; DRUG COMBINATIONS; FATTY ALCOHOLS; HUMANS; INFANT, NEWBORN; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPIDS; PROTEINS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 23244453923     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2005-0202     Document Type: Note

References (16)

1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child. 1959;97:517-523
2. Chu J, Clements JA, Cotton EK, et al. Neonatal pulmonary ischemia: clinical and physiological studies. Pediatrics. 1967;40:709-782
3. Hurt H, Kattwinkel J, Roth S. Artificial surfactant treatment in lambs with severe respiratory distress syndrome: a controlled study. J Pediatr. 1983;102:450-453
4. Durand DJ, Clyman RI, Heymann MA, et al. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs. J Pediatr. 1985;107:775-780
5. Morley CJ, Bangham AD, Miller N, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet. 1981;1(8211):64-68
6. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1(8159):55-59
7. Collaborative European Multicenter Study Group. Surfactant replacement therapy in severe neonatal respiratory distress syndrome; an international randomized clinical trial. Pediatrics. 1988;82:683-691
8. Kwong MS, Egan EA, Notter RH, Shapiro DL. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics. 1985;76:585-592
9. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;(2):CD000144
10. Whitsett JA, Hull WM, Luse S. Failure to detect surfactant proteinspecific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics. 1991;87:505-510
11. Chida S, Phelps DS, Soll RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics. 1991;88:84-89
12. Jobe AH, Ikegami M. Biology of surfactant. Clin Perinatol. 2001;28:655-669
13. Davis AJ, Jobe AH, Hafner D, Ikegami M. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med. 1998;157(2):553-559
14. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351:884-892
15. Moya FR, Gadzinowski J, Bancalari E, et al; for the International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005;115:1018-1029
16. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115:1030-1038